Gilead Sciences Acquires XinThera to Strengthen Early Pipeline in Oncology
Tuesday, May 09, 2023
Gilead Sciences announced the acquisition of all outstanding shares of XinThera. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation.
Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that will enter clinical trials later this year. In addition, this acquisition will allow to further expand early pipeline of diverse assets which will continue to fuel durable late-phase portfolio.
Gilead and XinThera share similar missions to discover new therapies to treat cancer and inflammatory diseases, driving determination to unlock the body’s ability to better respond to these diseases. Together this acquisition aims to explore the potential of precision medicines as critical components of the next generation of therapies targeting diseases with high unmet need.
